Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Klempner

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The Journal of Infectious Diseases|May 1, 1995
Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferiM S Klempner, R Noring, M P Epstein, et al.
The Journal of Infectious Diseases|February 18, 1998
Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosisG Perides, M E Charness, L M Tanner, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 10, 2004
Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosisR V Fleming, A R Marques, M S Klempner, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Neurology|June 25, 2003
Cognitive function in post-treatment Lyme disease: do additional antibiotics help?R F Kaplan, R P Trevino, G M Johnson, et al.
The New England Journal of Medicine|February 2, 1989
The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cellsS Endres, R Ghorbani, V E Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimeraE G Trehu, J W Mier, J S Dubois, et al.
The New England Journal of Medicine|July 14, 2001
Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme diseaseM S Klempner, L T Hu, J Evans, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 1998
Fellowship training in infectious diseases: a report from the regional and national meetings of infectious diseases division chiefs and program directorsK A Joiner, W G Powderly, M J Blaser, et al.
The New England Journal of Medicine|July 23, 1998
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study ConsortiumL H Sigal, J M Zahradnik, P Lavin, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The Journal of Infectious Diseases|May 1, 1995
Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferiM S Klempner, R Noring, M P Epstein, et al.
The Journal of Infectious Diseases|February 18, 1998
Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosisG Perides, M E Charness, L M Tanner, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 10, 2004
Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosisR V Fleming, A R Marques, M S Klempner, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Neurology|June 25, 2003
Cognitive function in post-treatment Lyme disease: do additional antibiotics help?R F Kaplan, R P Trevino, G M Johnson, et al.
The New England Journal of Medicine|February 2, 1989
The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cellsS Endres, R Ghorbani, V E Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimeraE G Trehu, J W Mier, J S Dubois, et al.
The New England Journal of Medicine|July 14, 2001
Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme diseaseM S Klempner, L T Hu, J Evans, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 1998
Fellowship training in infectious diseases: a report from the regional and national meetings of infectious diseases division chiefs and program directorsK A Joiner, W G Powderly, M J Blaser, et al.
The New England Journal of Medicine|July 23, 1998
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study ConsortiumL H Sigal, J M Zahradnik, P Lavin, et al.
Pageof 7